Clinical Trial Update: A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating safety and tolerability of PCS499 for necrobiosis lipoidica has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Necrobiosis Lipoidica

Drugs mentioned

• PCS499

Snippet

Sponsor: Processa Pharmaceuticals | Conditions: Necrobiosis Lipoidica | Phase 2 | Status: COMPLETED | Results posted: 2022-10-03